Attention, investors! There's a healthcare company that's been flying under the radar, and it's time to shine a light on its potential. Ebos Group Ltd, a powerhouse in both human and animal healthcare, is poised for a comeback, according to Macquarie's analysts.
Despite trading at $22.30, close to its 12-month low, and well below its highs, Ebos Group's shareholders might be in for a pleasant surprise. But here's where it gets controversial: Macquarie believes these shares are severely undervalued.
The company's shares took a hit last year, but the Macquarie team is confident that the worst is behind them. They've released a research note ahead of the company's results on February 25th, predicting a positive market reaction.
And this is the part most people miss: the company's Chair, Elizabeth Coutts, highlighted the attractive markets and supportive megatrends across their healthcare and animal care segments. She acknowledged near-term macro pressures but emphasized the company's long-term growth potential.
Macquarie's analysts see the risks as skewed towards the upside, with benefits from investments in distribution centers expected to flow in the current half-year. They've set a price target of NZ$39.78 (approximately $34.16) for Ebos Group's shares, which, combined with a 5% dividend yield, could result in a total shareholder return of 60.5%.
So, is Ebos Group Ltd a hidden gem in the healthcare sector? Will it surprise the market with its upcoming results? These are questions worth pondering. What are your thoughts? Feel free to share your opinions and predictions in the comments below!
